SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Nilsson Cecilia) "

Sökning: WFRF:(Nilsson Cecilia)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Ahlin, Cecilia, et al. (författare)
  • Cyclin A Is a Proliferative Marker with Good Prognostic Value in Node-Negative Breast Cancer.
  • 2009
  • Ingår i: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. - American Association for Cancer Research. - 1538-7755. ; 18, s. 2501-2506
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Proliferative markers are not recommended as prognostic factors for clinical use in breast cancer due to lack of standardization in methodology. However, proliferation is driving several gene expression signatures emphasizing the need for a reliable proliferative marker for clinical use. Studies suggest that cyclin A is a prognostic marker with satisfying reproducibility. We investigated cyclin A as a prognostic marker in node-negative breast cancer using previously defined cutoff values. Patients and METHODS: In a case-control study, we defined 190 women who died from breast cancer as cases and 190 women alive at the time for the corresponding case's death as controls. Inclusion criteria were tumor size </=50 mm, no lymph node metastases and no adjuvant chemotherapy. Tumor tissues were immunostained for cyclin A using commercially available antibodies. RESULTS: We found a statistically significant association between expression of cyclin A and breast cancer death in a univariate model: odds ratio for cyclin A(ave) 2.7 [95% confidence interval (CI), 1.7-4.3] and cyclin A(max) 3.4 (CI, 2.1-5.5). Corresponding odds ratio for Ki67 were Ki67(ave) 1.9 (CI, 1.2-3.1) and Ki67(max) 1.7 (CI, 1.1-2.7) and for grade 3.1 (CI, 1.8-5.1). Cyclin A was strongly correlated to Ki67 and grade why a model including all was not appropriate. CONCLUSIONS: Cyclin A is a prognostic factor for breast cancer death in node-negative patients using standardized methodology regarding scoring and cutoff values. Adding cyclin A as a proliferative marker to established clinicopathologic factors will improve the separation of low and high risk breast cancer. (Cancer Epidemiol Biomarkers Prev 2009;18(9):2501-6).
  •  
2.
  • Gad, Helge, et al. (författare)
  • MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool
  • 2014
  • Ingår i: Nature. - 1476-4687. ; 508:7495, s. 215-
  • Tidskriftsartikel (refereegranskat)abstract
    • Cancers have dysfunctional redox regulation resulting in reactive oxygen species production, damaging both DNA and free dNTPs. The MTH1 protein sanitizes oxidized dNTP pools to prevent incorporation of damaged bases during DNA replication. Although MTH1 is non-essential in normal cells, we show that cancer cells require MTH1 activity to avoid incorporation of oxidized dNTPs, resulting in DNA damage and cell death. We validate MTH1 as an anticancer target in vivo and describe small molecules TH287 and TH588 as first-in-class nudix hydrolase family inhibitors that potently and selectively engage and inhibit the MTH1 protein in cells. Protein co-crystal structures demonstrate that the inhibitors bind in the active site of MTH1. The inhibitors cause incorporation of oxidized dNTPs in cancer cells, leading to DNA damage, cytotoxicity and therapeutic responses in patient-derived mouse xenografts. This study exemplifies the non-oncogene addiction concept for anticancer treatment and validates MTH1 as being cancer phenotypic lethal.
  •  
3.
  • Ahlin, Cecilia, et al. (författare)
  • Cyclin A is a proliferative marker with good prognostic value in node-negative breast cancer
  • 2009
  • Ingår i: Cancer Epidemiology, Biomarkers and Prevention. - 1055-9965 .- 1538-7755. ; 18:9, s. 2501-2506
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Background: Proliferative markers are not recommended as prognostic   factors for clinical use in breast cancer due to lack of   standardization in methodology. However, proliferation is driving   several gene expression signatures emphasizing the need for a reliable   proliferative marker IF or clinical use. Studies suggest that cyclin A   is a prognostic marker with satisfying reproducibility. We investigated   cyclin A as a prognostic marker in node-negative breast cancer using   previously defined cutoff values.   Patients and Methods: In a case-control study, we defined 190 women who   died from breast cancer as cases and 190 women alive at the time for   the corresponding case's death as controls. Inclusion criteria were   tumor size &lt;= 50 mm, no lymph node metastases and no adjuvant   chemotherapy. Tumor tissues were immunostained for cyclin A using   commercially available antibodies.   Results: We found a statistically significant association between   expression of cyclin A and breast cancer death in a univariate model:   odds ratio for cyclin A(ave) 2.7 [95% confidence interval (CI),   1.7-4.3] and cyclin A(max) 3.4 (CI, 2.1-5.5). Corresponding odds ratio   for Ki67 were Ki67(ave) 1.9 (CI, 1.2-3.1) and Ki67(max) 1.7 (CI,   1.1-2.7) and for grade 3.1 (CI, 1.8-5.1). Cyclin A was strongly   correlated to Ki67 and grade why a model including all was not   appropriate.   Conclusions: Cyclin A is a prognostic factor for breast cancer death in   node-negative patients using standardized methodology regarding scoring   and cutoff values. Adding cyclin A as a proliferative marker to established clinicopathologic factors will improve the separation of  low and high risk breast cancer.</p>
  •  
4.
  • Ahlin, Cecilia, et al. (författare)
  • Cyclin A is a proliferative marker with good prognostic value in node-negative breast cancer
  • 2009
  • Ingår i: Cancer Epidemiology, Biomarkers and Prevention. - 1055-9965 .- 1538-7755. ; 18:9, s. 2501-2506
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Background: Proliferative markers are not recommended as prognostic factors for clinical use in breast cancer due to lack of standardization in methodology. However, proliferation is driving several gene expression signatures emphasizing the need for a reliable proliferative marker IF or clinical use. Studies suggest that cyclin A is a prognostic marker with satisfying reproducibility. We investigated cyclin A as a prognostic marker in node-negative breast cancer using previously defined cutoff values. Patients and Methods: In a case-control study, we defined 190 women who died from breast cancer as cases and 190 women alive at the time for the corresponding case's death as controls. Inclusion criteria were tumor size &lt;= 50 mm, no lymph node metastases and no adjuvant chemotherapy. Tumor tissues were immunostained for cyclin A using commercially available antibodies. Results: We found a statistically significant association between expression of cyclin A and breast cancer death in a univariate model: odds ratio for cyclin A(ave) 2.7 [95% confidence interval (CI), 1.7-4.3] and cyclin A(max) 3.4 (CI, 2.1-5.5). Corresponding odds ratio for Ki67 were Ki67(ave) 1.9 (CI, 1.2-3.1) and Ki67(max) 1.7 (CI, 1.1-2.7) and for grade 3.1 (CI, 1.8-5.1). Cyclin A was strongly correlated to Ki67 and grade why a model including all was not appropriate. Conclusions: Cyclin A is a prognostic factor for breast cancer death in node-negative patients using standardized methodology regarding scoring and cutoff values. Adding cyclin A as a proliferative marker to established clinicopathologic factors will improve the separation of low and high risk breast cancer. (Cancer Epidemiol Biomarkers Prev 2009;18(9):2501-6)</p>
  •  
5.
  • Bergström, Ulf, et al. (författare)
  • Effects of adalimumab treatment on endothelial cell activation markers in the skeletal muscle of patients with rheumatoid arthritis.
  • 2014
  • Ingår i: Clinical and Experimental Rheumatology. - Pacini. - 1593-098X. ; 32:6, s. 883-890
  • Tidskriftsartikel (refereegranskat)abstract
    • Patients with rheumatoid arthritis (RA), particularly those with severe disease, have increased risk of cardiovascular disease (CVD). Previous studies suggest that endothelial cell activation may contribute to this co-morbidity, and that treatment with tumour necrosis factor (TNF) inhibitors could reduce the risk of CVD in these patients. The aim of this study was to investigate endothelial cell activation markers in muscle tissue of patients after adalimumab treatment.
  •  
6.
  • Bi, Zhenwang, et al. (författare)
  • Prevalence of the mcr-1 colistin resistance gene in extended-spectrum beta-lactamase-producing Escherichia coli from human faecal samples collected in 2012 in rural villages in Shandong Province, China
  • 2017
  • Ingår i: International Journal of Antimicrobial Agents. - ELSEVIER SCIENCE BV. - 0924-8579 .- 1872-7913. ; 49:4, s. 493-497
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Since its initial discovery in China in 2015, the plasmid-mediated colistin resistance gene mcr-1 has been reported in Escherichia coli isolated from clinical samples, animals and meat worldwide. In this study, 706 extended-spectrum beta-lactamase (ESBL)-producing E. coli from 411 persons were detected in a collection of faecal samples from 1000 rural residents in three counties in Shandong Province, China. These isolates were screened for mcr-1 and phenotypic colistin resistance. The gene was found in 3.5% of the isolates (from 4.9% of persons) from all three counties. All isolates with phenotypic colistin resistance carried mcr-1. These data indicate that commensal carriage of ESBL-producing E. coli with mcr-1 among persons in rural China was already present in 2012 and that mcr-1 was the most important colistin resistance mechanism. Interventions are necessary to minimise further dissemination of mcr-1, which would limit the future usefulness of colistin as a last-resort antibiotic. (C) 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.</p>
  •  
7.
  • Bosco, Cecilia, et al. (författare)
  • Prostate Cancer Radiation Therapy and Risk of Thromboembolic Events
  • 2017
  • Ingår i: International Journal of Radiation Oncology Biology Physics. - Elsevier. - 0360-3016. ; 97:5, s. 1026-1031
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose To investigate the risk of thromboembolic disease (TED) after radiation therapy (RT) with curative intent for prostate cancer (PCa). Patients and Methods We identified all men who received RT as curative treatment (n=9410) and grouped according to external beam RT (EBRT) or brachytherapy (BT). By comparing with an age- and county-matched comparison cohort of PCa-free men (n=46,826), we investigated risk of TED after RT using Cox proportional hazard regression models. The model was adjusted for tumor characteristics, demographics, comorbidities, PCa treatments, and known risk factors of TED, such as recent surgery and disease progression. Results Between 2006 and 2013, 6232 men with PCa received EBRT, and 3178 underwent BT. A statistically significant association was found between EBRT and BT and risk of pulmonary embolism in the crude analysis. However, upon adjusting for known TED risk factors these associations disappeared. No significant associations were found between BT or EBRT and deep venous thrombosis. Conclusion Curative RT for prostate cancer using contemporary methodologies was not associated with an increased risk of TED.
8.
  • Burman, Joachim, et al. (författare)
  • Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience
  • 2014
  • Ingår i: Journal of Neurology, Neurosurgery and Psychiatry. - BMJ Publishing Group. - 1468-330X. ; 85:10, s. 1116-1121
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Autologous haematopoietic stem cell transplantation (HSCT) is a viable option for treatment of aggressive multiple sclerosis (MS). No randomised controlled trial has been performed, and thus, experiences from systematic and sustained follow-up of treated patients constitute important information about safety and efficacy. In this observational study, we describe the characteristics and outcome of the Swedish patients treated with HSCT for MS. Methods Neurologists from the major hospitals in Sweden filled out a follow-up form with prospectively collected data. Fifty-two patients were identified in total; 48 were included in the study and evaluated for safety and side effects; 41 patients had at least 1 year of follow-up and were further analysed for clinical and radiological outcome. In this cohort, 34 patients (83%) had relapsing-remitting MS, and mean follow-up time was 47 months. Results At 5 years, relapse-free survival was 87%; MRI event-free survival 85%; expanded disability status scale (EDSS) score progression-free survival 77%; and disease-free survival (no relapses, no new MRI lesions and no EDSS progression) 68%. Presence of gadolinium-enhancing lesions prior to HSCT was associated with a favourable outcome (disease-free survival 79% vs 46%, p=0.028). There was no mortality. The most common long-term side effects were herpes zoster reactivation (15%) and thyroid disease (8.4%). Conclusions HSCT is a very effective treatment of inflammatory active MS and can be performed with a high degree of safety at experienced centres.
  •  
9.
  • Cars, Otto, et al. (författare)
  • Building bridges to operationalise one health A Sino-Swedish collaboration to tackle antibiotic resistance
  • 2016
  • Ingår i: One Health. - Elsevier. - 2352-7714. ; 2, s. 139-143
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Antibiotic resistance is a complex global health challenge. The recent Global Action Plan on antimicrobial resistance highlights the importance of adopting One Health approaches that can cross traditional disciplinary boundaries. We report on the early experiences of a multisectoral Sino-Swedish research project that aims to address gaps in our current knowledge and seeks to improve the situation through system-wide interventions. Our research project is investigating antibiotic use and resistance in a rural area of China through a combination of epidemiological, health systems and laboratory investigations. We reflect here on the challenges inherent in conducting long distance cross-disciplinary collaborations, having now completed data and sample collection for a baseline situation analysis. In particular, we recognise the importance of investing in aspects such as effective communication, shared conceptual frameworks and leadership. We suggest that our experiences will be instructive to others planning to develop similar international One Health collaborations. (c) 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</p>
  •  
10.
  • Cederfur, Cecilia, et al. (författare)
  • Different affinity of galectins for human serum glycoproteins: galectin-3 binds many protease inhibitors and acute phase proteins.
  • 2008
  • Ingår i: Glycobiology. - Oxford University Press. - 1460-2423. ; 18:5, s. 384-394
  • Tidskriftsartikel (refereegranskat)abstract
    • Here we report the first survey of galectin binding to glycoproteins of human serum. Serum was subjected to affinity chromatography using immobilized galectins, and the bound glycoproteins were analyzed by electrophoresis, Western blotting, and mass spectrometry. Galectins-3, -8 and -9 bound a much broader range of ligands in serum than previously known, galectin-1 bound less, and galectins-2, -4 and -7 bound only traces or no serum ligands. Galectin-3 bound most major glycoproteins, including alpha-2 macroglobulin and acute phase proteins such as haptoglobin. It bound only a selected minor fraction of transferrin, and bound none or little of IgG. Galectin-8 and -9 bound a similar range of glycoproteins as galectin-3, but in lower amounts, and galectin-8 had a relative preference for IgA. Galectin-1 bound mainly a fraction of alpha-2 macroglobulin and only traces of other glycoproteins. The binding of galectin-3 to serum glycoproteins requires affinity for LacNAc, since a mutant (R186S), which has lost this affinity, did not bind any serum glycoproteins. The average affinity of galectin-3 for serum glycoproteins was estimated to correspond to K(d) approximately 1-5 muM by modelling of the affinity chromatography and a fluorescence anisotropy assay. Since galectins are expressed on endothelial cells and other cells exposed to serum components, this report gives new insight into function of galectins and the role of their different fine specificity giving differential binding to the serum glycoproteins.
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (82)
Typ av publikation
tidskriftsartikel (361)
konferensbidrag (35)
annan publikation (15)
rapport (14)
doktorsavhandling (11)
bokkapitel (8)
visa fler...
forskningsöversikt (7)
bok (3)
proceedings (redaktörskap) (3)
samlingsverk (redaktörskap) (2)
licentiatavhandling (1)
visa färre...
Typ av innehåll
refereegranskat (385)
övrigt vetenskapligt (105)
populärvet., debatt m.m. (7)
Författare/redaktör
Nilsson, Peter, (70)
Nilsson, Cecilia, (61)
Johansson, Cecilia, (31)
Lind, Lars, (29)
Lindgren, Cecilia M. (28)
Leppert, Jerzy (24)
visa fler...
Kuusisto, Johanna, (23)
Laakso, Markku, (23)
Boehnke, Michael (23)
Uhlén, Mathias, (22)
Wareham, Nicholas J (22)
McCarthy, Mark I (22)
Langenberg, Claudia (22)
Barroso, Inês (22)
Hattersley, Andrew T (22)
Frayling, Timothy M. (22)
Nilsson, Peter M, (21)
Mohlke, Karen L (21)
Zeggini, Eleftheria (21)
Tuomi, Tiinamaija, (20)
Groop, Leif, (20)
Pedersen, Nancy L (20)
Pomp, Stephan, (20)
Nadel-Turonski, P., (20)
Jackson, Anne U. (20)
Morris, Andrew P. (20)
Schwenk, Jochen M., (20)
Dupuis, Josée (20)
Meigs, James B. (20)
Lyssenko, Valeriya, (19)
Olsson, N (19)
Perry, John R. B. (19)
Illig, Thomas (19)
Stringham, Heather M ... (19)
Tuomilehto, Jaakko (19)
Tippawan, Udomrat (19)
Altshuler, David (19)
Morris, Andrew D (19)
Hedenfalk, Ingrid, (18)
Melander, Olle, (18)
Blomgren, Jan (18)
Pedersen, Oluf, (18)
Hansen, Torben, (18)
Ingelsson, Erik (18)
Qi, Lu (18)
Prokopenko, Inga (18)
Bergman, Richard N. (18)
Collins, Francis S. (18)
Jonsson, O. (18)
Balkau, Beverley (18)
visa färre...
Lärosäte
Uppsala universitet (147)
Lunds universitet (99)
Göteborgs universitet (43)
Kungliga Tekniska Högskolan (36)
Linköpings universitet (32)
Karolinska Institutet (19)
visa fler...
Umeå universitet (16)
Stockholms universitet (16)
Linnéuniversitetet (15)
Chalmers tekniska högskola (13)
Karlstads universitet (8)
Örebro universitet (7)
Högskolan i Jönköping (6)
Sveriges Lantbruksuniversitet (6)
Mittuniversitetet (5)
Mälardalens högskola (4)
Högskolan i Halmstad (3)
RISE (3)
Blekinge Tekniska Högskola (3)
Luleå tekniska universitet (2)
Högskolan Kristianstad (2)
swepub_uni:mau_t (2)
Naturvårdsverket (2)
Högskolan Väst (1)
Södertörns högskola (1)
Högskolan i Skövde (1)
Kungl. Musikhögskolan (1)
Gymnastik- och idrottshögskolan (1)
Naturhistoriska riksmuseet (1)
visa färre...
Språk
Engelska (414)
Svenska (29)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (275)
Naturvetenskap (77)
Samhällsvetenskap (56)
Teknik (26)
Lantbruksvetenskap (13)
Humaniora (11)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy